Evogene Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ofer Haviv
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 13 Gad Feinstein Street Rehovot HM Israel 7638517
- IPO Date
- Oct 15, 2010
- CIK
- 0001574565
- Website
- evogene.com
- Similar Companies
- Business
- Evogene Ltd. (NASDAQ: EVGN; TASE: EVGN.TA) operates as a computational biology company that leverages artificial intelligence, machine learning, and big data through its Computational Predictive Biology (CPB) platform to discover and develop life-science products based on microbes, small molecules, and genetic elements; the company serves industries including human health, agriculture, and industrial applications. It maintains three core technological engines--MicroBoost AI for microbe-based products such as human microbiome therapeutics via subsidiary Biomica Ltd., ag-biologicals, and industrial microbes; ChemPass AI for small molecule-based products including pharmaceuticals and ag-chemicals via subsidiary AgPlenus Ltd.; and GeneRator AI for genetic element-based products such as seed traits and castor ag-solutions via subsidiary Casterra Ag Ltd.--with operations spanning Israel, the United States, Brazil, and internationally. Founded in 1999 and headquartered in Rehovot, Israel, Evogene targets pharmaceutical developers, agricultural companies, and industrial firms with predictive solutions that accelerate product development while reducing costs and risks. In a significant strategic shift, the company completed the divestiture of the majority of its ag-biologicals subsidiary Lavie Bio Ltd.'s activities and assets--including the proprietary Biology Driven Design platform, microbial bank, product pipeline, and MicroBoost AI for AG tech-engine--to ICL Group Ltd. in July 2025, pursuant to an agreement announced in April 2025, enabling focus on core platforms and unlocking subsidiary value while Lavie Bio retains certain partnerships for potential future revenue.
Company News
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript
EverGen Infrastructure Reports Q2 2026 Results
EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026
EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
Evogene Reports Second Quarter and First Half 2026 Financial Results
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Evogene (NASDAQ:EVGN) Stock Price Passes Below 200 Day Moving Average – Here’s Why
Evogene Schedules Second Quarter 2026 Financial Results Release
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
EverGen Infrastructure Announces Share Issuance to Officers and Directors of the Company
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript
EverGen Infrastructure Reports Q1 2026 Results